Literature DB >> 10679202

Cloning and characterization of a novel adaptor protein, CIN85, that interacts with c-Cbl.

H Take1, S Watanabe, K Takeda, Z X Yu, N Iwata, S Kajigaya.   

Abstract

The c-Cbl protooncogene product is a prominent substrate of protein tyrosine kinases and is rapidly tyrosine-phosphorylated upon stimulation of a wide variety of cell-surface receptors. We have identified a novel c-Cbl-interacting protein termed CIN85 with a molecular mass of 85 kDa which shows similarity to adaptor proteins, CMS and CD2AP. CIN85 mRNA is expressed ubiquitously in normal human tissues and cancer cell lines analyzed. CIN85 was basally associated with c-Cbl. For interaction of CIN85 with c-Cbl, the second SH3 domain of CIN85 was shown to serve as a central player. The CIN85-c-Cbl association was enhanced shortly after stimulation of 293 cells with epidermal growth factor (EGF) and gradually diminished to a basal level, which correlated with a tyrosine phosphorylation level of c-Cbl. Our results suggest that CIN85 may play a specific role in the EGF receptor-mediated signaling cascade via its interaction with c-Cbl. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679202     DOI: 10.1006/bbrc.2000.2147

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  47 in total

1.  Negative regulation of PI 3-kinase by Ruk, a novel adaptor protein.

Authors:  I Gout; G Middleton; J Adu; N N Ninkina; L B Drobot; V Filonenko; G Matsuka; A M Davies; M Waterfield; V L Buchman
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

2.  A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway.

Authors:  Takahiro Wakasaki; Muneyuki Masuda; Hiroaki Niiro; Siamak Jabbarzadeh-Tabrizi; Kumiko Noda; Tadayoshi Taniyama; Shizuo Komune; Koichi Akashi
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

3.  ARAP1 association with CIN85 affects epidermal growth factor receptor endocytic trafficking.

Authors:  Hye-Young Yoon; Stephen C Kales; Ruibai Luo; Stanley Lipkowitz; Paul A Randazzo
Journal:  Biol Cell       Date:  2011-04       Impact factor: 4.458

4.  Cbl-directed monoubiquitination of CIN85 is involved in regulation of ligand-induced degradation of EGF receptors.

Authors:  Kaisa Haglund; Noriaki Shimokawa; Iwona Szymkiewicz; Ivan Dikic
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

Review 5.  Cargo- and compartment-selective endocytic scaffold proteins.

Authors:  Iwona Szymkiewicz; Oleg Shupliakov; Ivan Dikic
Journal:  Biochem J       Date:  2004-10-01       Impact factor: 3.857

6.  CIN85 associates with multiple effectors controlling intracellular trafficking of epidermal growth factor receptors.

Authors:  Katarzyna Kowanetz; Koraljka Husnjak; Daniela Höller; Marcin Kowanetz; Philippe Soubeyran; Dianne Hirsch; Mirko H H Schmidt; Kresimir Pavelic; Pietro De Camilli; Paul A Randazzo; Ivan Dikic
Journal:  Mol Biol Cell       Date:  2004-04-16       Impact factor: 4.138

7.  SH3KBP1-binding protein 1 prevents epidermal growth factor receptor degradation by the interruption of c-Cbl-CIN85 complex.

Authors:  Lifeng Feng; Jin-Tao Wang; Hongchuan Jin; Kaixian Qian; Jian-Guo Geng
Journal:  Cell Biochem Funct       Date:  2011-08-09       Impact factor: 3.685

8.  Dynamin forms a Src kinase-sensitive complex with Cbl and regulates podosomes and osteoclast activity.

Authors:  Angela Bruzzaniti; Lynn Neff; Archana Sanjay; William C Horne; Pietro De Camilli; Roland Baron
Journal:  Mol Biol Cell       Date:  2005-05-04       Impact factor: 4.138

Review 9.  T-cell activation and immunologic synapse.

Authors:  Andrey S Shaw
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

10.  Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization.

Authors:  Mirko H H Schmidt; Frank B Furnari; Webster K Cavenee; Oliver Bögler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.